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Heat shock protein 90 (Hsp90) is a promising cancer drug target as a molecular
chaperone critical for stabilization and activation of several of the oncoproteins
that drive cancer progression. Its actions depend upon its essential ATPase, an
activity fortuitously inhibited with a very high degree of selectivity by natural
antibiotics: notably the actinomycete-derived benzoquinone ansamycins (e.g.
geldanamycin) and certain fungal-derived resorcyclic acid lactones (e.g. radici-
col). The molecular interactions made by these antibiotics when bound within
the ADP/ATP-binding site of Hsp90 have served as templates for the develop-
ment of several synthetic Hsp90 inhibitor drugs. Much attention now focuses
on the clinical trials of these drugs. However, because microbes have evolved
antibiotics to target Hsp90, it is probable that they often exploit Hsp90 inhi-
bition when interacting with each other and with plants. Fungi known to
produce Hsp90 inhibitors include mycoparasitic, as well as plant-pathogenic,
endophytic and mycorrhizal species. The Hsp90 chaperone may, therefore, be
a prominent target in establishing a number of mycoparasitic (interfungal),
fungal pathogen–plant and symbiotic fungus–plant relationships. Furthermore
the Hsp90 family proteins of the microbes that produce Hsp90 inhibitor anti-
biotics are able to reveal how drug resistance can arise by amino acid
changes in the highly conserved ADP/ATP-binding site of Hsp90.2. Introduction
Heat shock protein 90 (Hsp90) is essential for the conformational maturation, acti-
vation and maintenance of proteins needed for all of the six hallmarks of cancer:
angiogenesis, immortalization, metastasis, impaired apoptosis, insensitivity to
antigrowth signals and autocrine growth [1,2]. As a result, this promiscuous mol-
ecular chaperone is a prime target for drug development, with 13 Hsp90 inhibitor
compounds now being in phase I/II clinical trials for the treatment of various
cancers [1,2]. Not only does the continual growth of these cells in hostile micro-
environments need sustained Hsp90 chaperone activity, but the Hsp90 in
cancer cells has a higher affinity for Hsp90 inhibitor drugs than the Hsp90
in normal cells, a reflection of the high levels of Hsp90-dependent protein com-
plexes in cancer cells [3]. It is probable that Hsp90 inhibitor drugs will, in due
course, find applications in a number of other therapies. Because they are
potent activators of the heat shock response, one of their actions is to elevate cel-
lular levels of the molecular chaperones that assist protein folding. This, in turn,
can help to restore losses of proteostasis and thus ameliorate the effects of those
diseases that are caused by loss of proper protein conformation (e.g. cystic fibrosis,
as well as neurodegenerative diseases of ageing [4–6]). In addition, Hsp90 inhibi-
tors are of potential use for the treatment of infectious disease, because in
eukaryotic cells Hsp90 is essential for the replication of both viruses (e.g.
Table 1. Natural product inhibitors of Hsp90.
sourced from microbes:
benzoquinone ansamycins antibiotics derived from actinomycetes; notably geldanamycin (GdA) from Streptomyces hygroscopicus var. geldanus [9];
herbimycin A from S. hygroscopicus strain AM-3672 [10]; and macbecin 1 from Nocardia sp. No C-14919 [11]
RAD and pochonins;
(ﬁgure 2).
resorcyclic acid lactones produced by several fungi of the Sordariomycetes taxon; pochonins A and D from Pochonia
chlamydosporia have been shown to directly inhibit Hsp90 [12]
novobiocin, coumermycin
A1, clorobiocin
coumermycin family antibiotics from Streptomyces spheroides; bind the C-terminal region of Hsp90 [13]
sourced from plants:
harmine an alkaloid from the African medicinal plant Guiera senegalensis; displays a higher afﬁnity for the N-terminal domain of
Hsp90 from the malaria parasite Plasmodium falciparum than the corresponding domain of the human Hsp90 [14]
epigallocatechin-3-gallate a naturally occurring polyphenol from the green tea, Camellia sinensis; binds the C-terminal domain of Hsp90 [15]
derrubone a prenylated isoﬂavone isolated from the Indian tree Derris robusta [16]
gedunin and celastrol triterpenes isolated from the Indian neem tree Azadirachta indica [17]; celastrol binds the Hsp90 C-terminal domain [18]
withaferin A a steroidal lactone from the Indian medicinal plant Withania somnifera; binds C-terminal domain of Hsp90 [19]
gambogic acid a compound from the plant species Garcinia hanburyi; binds the N-terminal domain of Hsp90 at a site distinct from the
ADP/ATP-binding pocket [20]
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2picornaviruses [7]) and pathogenic microbes (e.g. the malaria
parasite Plasmodium falciparum [8]).3. The discovery of natural product
inhibitors of heat shock protein 90
The appreciation that Hsp90 might be a valuable drug target
was initially slow in coming. It was initiated by studies on
the actions of benzoquinone ansamycins (table 1), actinomy-
cete-derived antibiotics of very closely related structure
(figure 1), in mammalian cell culture. In 1970, geldanamycin
(GdA) was reported as exerting potent activity against L1210
mouse leukaemia and KB cells [9]. Later a modified form of
GdA (17-dimethylamino-geldanamycin) was found to be 20-
fold more potent against v-src tyrosine kinase-transformed
3Y1 cells as compared with the untransformed parental
3Y1 cells, providing the first indication that cancer cells may
be particularly susceptible to derivatives of GdA [22]. This,
in turn, was followed by the landmark discoveries that an
immobilized form of GdA binds Hsp90, and also that GdA
and herbimycin A act to reverse the oncogenic transformation
of fibroblasts by v-src tyrosine kinase by blocking the for-
mation of the Hsp90–v-src heteroprotein complex [23]. GdA
was subsequently shown to promote the degradation of a
number of Hsp90-dependent (Hsp90 ‘client’) proteins in vivo
[24], and to inhibit the ATPase activity of Hsp90 through bind-
ing, with very high degree of selectivity [25], within the ADP/
ATP-binding site of the Hsp90 N-terminal domain [26,27]. A
little later radicicol/monorden (RAD) (figure 2a; table 1), a
non-ansamycin fungal-derived antibiotic that had previously
also been found to revert the transformed phenotype of
v-src-expressing fibroblasts [29], was found to bind within
this same ADP/ATP-binding site on Hsp90, but by making
substantially different bonding interactions within this
chaperone site [30]. Several benzoquinone ansamycin deriva-
tives [31], as well as a number of small molecule syntheticinhibitor compounds based on the interactions of RAD, are
now in clinical trials [1,2].
Since these discoveries of Hsp90 as the target of the ben-
zoquinone ansamycins and RAD, several other natural
compounds—including a number derived from medicinal
plants—have been found to bind, and inhibit, this chaperone
(table 1). Each of these is now providing a lead for further
drug development [20,32]. However, in this review, we
focus solely on the benzoquinone ansamycins and the
fungal-derived resorcyclic acid lactones (RALs), because
these are the natural inhibitors where high-resolution crystal
structures have revealed in atomic detail the interactions
made as they bind within the Hsp90 N-terminal domain.
Also RAD (an RAL; figure 2c) is still the most potent natural
product inhibitor of Hsp90 discovered to date (binding to
Hsp90 with a Kd of 19 nM [30]). We suggest why the
microbial species producing these secondary metabolites
might exploit Hsp90 inhibition. We also discuss how the
Hsp90 family proteins of these microbes can provide insights
into how the extremely conserved ADP/ATP-binding pocket
of Hsp90 can be altered to generate forms of Hsp90 with a
degree of resistance to these antibiotics. Because the Hsp90
inhibitor drugs in cancer clinical trials all act by binding
within an almost identical ADP/ATP pocket on the
corresponding human Hsp90s, these microbial Hsp90s pro-
vide an indication of whether the Hsp90 in cancer cells
may be able to mutate this site to drug resistance, yet still
remain functional.4. Why might Streptomyces hygroscopicus
use heat shock protein 90 as an
antibiotic target?
Streptomycetes are soil-dwelling mycelial bacteria forming
sporulating aerial branches. Streptomyces hygroscopicus—the
organism producing GdA and herbimycin A (figure 1)—
geldanamycin herbimycin A macbecin 1NH2NH2 NH2
19
21 1
4
5
O
O
O
O
O
O
OH
MeO
O
O
O
O
O
O
O
O
N
H NH
N
H
O
O
O
O
O
O
O
O(a)
(b)
O
O
7
11
15
17
Figure 1. (a) Benzoquinone ansamycins studied as Hsp90 inhibitors: geldanamycin (GdA), herbimycin A and macbecin 1. (b) GdA, shown in yellow, in the
conformationally constrained trans-conformation that it adopts when bound within the N-terminal domain of the yeast Hsp90 (PDB ID: 1A4H). Hsp90 residues
forming its binding site that are conserved in the HtpG of the GdA-producing organism S. hygroscopicus are shown in blue, whereas those in this site that are altered
in the S. hygroscopicus HtpG are shown in light or dark brown. The two polar residues indicated in dark brown are the ones which generated partial resistance to
GdA in yeast cells when altered to S. hygroscopicus HtpG-specific residues in the native Hsp90 of yeast [21].
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3belongs to the Streptomyces violaceusniger clade of these bac-
teria, a clade that is attracting interest both for its
production of secondary metabolites and for its abilities to
antagonize the growth of a number of plant-pathogenic
fungi [33]. The S. hygroscopicus gene clusters directing the bio-
synthesis of GdA and herbimycin A are well characterized
[34]. Synthesis of both compounds entails a chain extension
from the basic ‘building block’ of the ansamycins, 3-amino-
5-hydroxybenzoic acid, this chain extension and a subsequent
cyclization producing the polyketide synthase (PKS)-derived
carbon skeleton (progeldanamycin), upon which various
post-PKS modification enzymes act to produce the differ-
ences in substitution patterns at carbon positions 11, 15,and 17 (figure 1a; for details see [34]). Though a full chemical
synthesis of GdA has been achieved, it entailed 20 steps and a
low overall yield [35]. The production of benzoquinone
ansamycin-based drugs is therefore usually achieved by
chemical modification of the GdA or herbimycin A derived
from S. hygroscopicus fermentation. However, both the natural
benzoquinone ansamycins (figure 1a), as well as their chemi-
cally-modified forms, have severe drawbacks in clinical
use owing to their low solubility and the redox activity of
the benzoquinone ring. The benzoquinone, through redox
cycling and the production of the unstable semiquinone
radical, is able to generate appreciable oxidative stress
in vivo [36]. For this reason S. hygroscopicus has recently been
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Figure 2. (a– c) Fungal-derived resorcyclic acid lactones: (a) hypothemycin and zearalenone; (b) the monocillins; (c) RAD, pochonin A and pochonin D, chlorinated
forms of the monocillins that are inhibitors of Hsp90. (d) A simplified version of the RAD biosynthetic pathway, involving the sequential actions of a reducing
polyketide synthase (R-PKS), a non-reducing PKS (NR-PKS), a halogenase and a P450 oxygenase [28].
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4genetically engineered for the production of new non-
quinone analogues of GdA, compounds with a better
pharmacological profile than the natural antibiotics [37].
Without the unravelling of the details of GdA and herbimy-
cin A biosynthesis [34], this could not have been achieved.
Intuitively one suspects that streptomycetes must produce
antibiotics so as to have a competitive advantage against the
other micro-organisms that they encounter. However, because
antibiotic production is usually delayed until most of the
growth has been completed, its main purpose may be to
defend the colony biomass against overgrowth by other organ-
isms rather than help in the competition for primary biomass
accumulation. While the extracellular biology of streptomy-
cetes is extremely complex, it is known that these species
often establish close interactions with fungal hyphae [38].
Furthermore, a number of potent inhibitors of fungal growth
(e.g. hygromycin B, nigericin, rapamycin) are amongst the
diverse range of antibiotics produced by different isolatesof S. hygroscopicus. Potentially the Hsp90 of fungi may be an
ideal target for yet another actinomycete-produced antibiotic,
because this chaperone is critical for a number of the activities
needed for biosynthesis of the cell wall and the response to cell
wall stress in fungal cells [39,40]. The production of Hsp90
inhibitors by certain S. hygroscopicus may, therefore, help
these streptomycetes inhibit the fungi in soil.5. Why might fungi use heat shock protein
90 as an antibiotic target?
The fungal-derived Hsp90 inhibitors in table 1 are a subset of
a diverse range of RALs produced by different fungal species.
The biosynthesis of two of these RALs—hypothemycin and
zearalenone (figure 2a)—is particularly well characterized,
the synthesis of zearalenone having being studied in both
Gibberella and Fusarium species (see [41] for literature). In
rsob.royalsocietypublishing.org
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5essence, fungal RALs are initially built up from units of
malonyl-CoA through the sequential actions of a reducing
polyketide synthase (R-PKS) and a non-reducing PKS (NR-
PKS; figure 2d), then subsequently acquiring much of their
structural diversity through different post-PKS modification
reactions. The pathway of RAD biosynthesis has been revealed
with analysis of the RAD biosynthetic gene clusters of two
species: Chaetomium chiversii [42] and Pochonia chlamydosporia
[28,41]. Each gene cluster encodes an R-PKS, a NR-PKS and
just two post-PKS tailoring enzymes, a cytochrome P450 and
a non-haeme halogenase. The latter introduce the epoxide
and the chlorine, respectively (figure 2d) [28].
Diverse fungi are currently identified as producers of the
structurally similar RAD, the pochonins or the monocillins
(figure 2b,c). They include mycopathogens, plant pathogens, as
well as species forming endophytic or mycorrhizal symbioses
with plants. As long ago as 1950, RAD and its unchlorinated
monocillin precursor (figure 2b) were identified in Monocillium
nordinii, a destructive mycoparasite of pine stem rusts in North
America [43]. It was later suggested that these compounds
might play a key role in the mycoparasitic actions of this
M. nordinii [44]. Often remarkably high amounts of RAD, pocho-
nins or monocillins have been found in fungal extracts. High
RAD production was identified for Cylindrocarpon radicicola, a
fungus isolated from the mycorrhizal tuberous roots of a sapro-
phytic orchid [45]. Monocillin was present at approximately 30
per cent by weight in dry extracts of Paraphaeosphaeria quadrisep-
tata, a fungus that inhabits the rhizosphere of cacti as well as
young maize plants [46,47]. Similarly, up to 10 per cent RAD
was identified in extracts of the above-mentioned Chaetomium
chiversii, an endophytic fungus that colonizes plant stem tissue
[48]. This efficient production of Hsp90 inhibitor compounds
may reflect the Hsp90 chaperone being a prominent target in
the establishment of certain parasitic (mycoparasitic, nemato-
phagous), plant-pathogenic (fungal pathogen–plant) and
symbiotic fungal–plant interactions.
Parasitic fungi may potentially have a very important
ecological impact through their actions of reducing the popu-
lations of nematodes and fungal oospores in soil. They have,
therefore, attracted attention as possible agents for the
biocontrol of these plant pathogens. The RAD and pocho-
nin-producer Pochonia chlamydosporia, mentioned above,
infects and destroys the eggs of root knot and cyst nematodes
[49]. Another RAD-producing species, the mycoparasitic
fungus Humicola fuscoatra, negatively impacts on a number
of the important oomycete plant-pathogenic fungi (e.g.
species of the Phytophthora genus) by infecting their oospores
in soil [50]. Extracts of this and other RAD- and monocillin-
producing fungi have been under consideration for the bio-
control of Aspergillus flavus and Fusarium verticillioides, two
mycotoxin-producing, seed-infecting fungal pathogens
[50,51]. While the events whereby a mycoparasitic fungus
invades oospores have been studied by microscopy [52],
there appears to have been little detailed investigation of
whether the production of an Hsp90 inhibitor by such a
species might impact on this process.
Production of Hsp90 inhibitors by fungi might also reflect
the importance of Hsp90 in the plant defence against patho-
gens. Pathogen entry to a host plant is accompanied by a
local defence response. Instrumental in this response are the
plant immune sensing NLR (nucleotide-binding domain
and leucine-rich repeat containing) proteins. NLR proteins
are ‘clients’ of the Hsp90 chaperone [53,54], whose rapiddegradation in Hsp90-deficient mutant plants results in a
greater sensitivity to microbial pathogens [55]. Oomycete
pathogens such as species of Phytophthora suppress this
immune response by secreting into the plant cells effector
proteins, the latter defined by an RXLR host cell entry
motif [56]. With the additional production of an Hsp90
inhibitor able to target the Hsp90 needed for the stability of
the plant’s NLR proteins, this effector protein action should
be potentiated. It has been suggested that the RAD and
monocillin production displayed by the maize pathogen
Colletotrichum graminicolamay assist the fungus by disrupting
the maize plant defences this way and by excluding other
fungi from necrotic tissues [51].
As regards an endophytic fungal/plant or mycorrhizal
fungal/plant symbiosis, the fungal production of an Hsp90
inhibitor may be perceived as facilitating the establishment
and maintenance of the symbiotic relationship in two ways.
First, it may lead to the selective inhibition of other fungi,
including some potential plant pathogens. Second, by sup-
pressing the activity of the plant Hsp90, it may compromise
the plant immune (NLR protein) sensing system and lead
to the induction of stress (heat shock) proteins [47]. Entry of
a mycorrhizal fungus to the root system of a host plant is
known to be accompanied by a local defence response, simi-
lar to the response to pathogens. Establishment of the
symbiotic relationship may be facilitated if this defence
response is suppressed.6. What can the organisms that make heat
shock protein 90 inhibitors tell us about
heat shock protein 90 inhibitor
resistance?
Resistance acquired through mutation of the drug target still
remains one of the most serious causes of the failure of cancer
chemotherapy. This is highlighted by the treatments with
highly selective inhibitors of oncogenic tyrosine kinases,
where many patients with advanced stage disease respond
initially but then relapse. Analysis of clinical samples has
shown that resistance to the Bcr-Abl kinase inhibitor imatinib
generally arises either though Bcr-Abl gene amplification or
with a single amino acid substitution in the Abl kinase
domain [57]. The latter, a change to the ‘gatekeeper’ residue,
a threonine that engages in a critical hydrogen bond with the
drug molecule bound within the Abl kinase domain, is a
‘generic’ resistance mutation that threatens to reduce the
potency of any ATP-competitive inhibitor designed against
a tyrosine kinase. Mutation of this gatekeeper threonine is
also the cause of resistance to drugs that target the mutated
forms of the epidermal growth factor receptor, a situation
where its primary effect is not to compromise drug binding,
but to increase the affinity of the kinase domain for ATP [58].
The Hsp90 inhibitors in clinical trials present the distinct
advantage that resistance would not arise this way. While
these drugs are also competitive inhibitors of ATP binding,
their mode of binding to their target is very different from
that of the above protein kinase inhibitors. Hsp90 is a
member of a protein superfamily with novel ATP-binding
properties, a superfamily that includes such diverse proteins
as DNA topoisomerase II, DNA mismatch repair enzymes
MutL and histidine kinases. The singular unifying feature
rsob.royalsocietypublishing.org
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6of this superfamily is the unconventional Bergerat ATP-bind-
ing fold, a site where ATP binds with its ribose ring in the
C30-endo conformation, rather than with the ribose in the
more usual C20-endo configuration as seen in the classical
mode of ATP binding by kinase enzymes [27].
This ADP/ATP-binding pocket on Hsp90 is evolutiona-
rily very highly conserved, being composed of essentially
identical amino acid residues in practically all Hsp90 family
proteins from eubacteria through to eukaryotes. A mutation
causing drug resistance by weakening the binding of the
drug within this site would involve changing one of these
invariant residues. As these are the amino acids that facilitate
the ATP binding or ATPase steps of the Hsp90 chaperone
cycle, such a mutation would be expected to severely
compromise, if not totally inactivate, Hsp90. We have been
investigating the Hsp90 family proteins of microbes
that make GdA or RAD on the premise that, should nature
have been able to evolve a drug resistant form of
Hsp90 altered in this site, it would most probably occur in
these species so as to confer a degree of resistance to this
antibiotic production.
A single Hsp90 family protein (HtpG) is encoded within
the genome of S. hygroscopicus var. geldanus, the organism
that makes GdA [21]. When purified following bacterial
expression, this S. hygroscopicus HtpG was found to display
normal binding affinities for nucleotides and RAD, but no
detectable binding of benzoquinone ansamycins [21]. It,
therefore, provides a blueprint for an Hsp90 that retains
the binding of nucleotides and RAD, yet fails to bind
GdA. Within this S. hygroscopicus HtpG, there are changes
to several of the conserved amino acids that facilitate the
interactions with GdA in the cocrystal structures of this anti-
biotic bound to eukaryotic forms of Hsp90 [26,30]. Most of
these changes lie on one side of the drug-binding pocket
(figure 1b). Unexpectedly, we found that these amino acid
substitutions found in the S. hygroscopicus HtpG did not
lead to loss of the essential Hsp90 function when introduced
into the sole Hsp90 of a model eukaryotic cell (the yeast
Saccharomyces cerevisiae). Therefore, the ADP/ATP-binding
pocket of Hsp90, though highly conserved in evolution, is
still amenable to mutational change. Furthermore, most of
these amino acid changes did not generate GdA resistance
when inserted into the Hsp90 of yeast. Only two of them
generated partial resistance, these (the mutations E88G
and N92L) involving replacement of polar amino acid side
chains for uncharged side chains on a small a-helix that
comprises one face of the ADP/ATP-binding pocket
(figure 1b). Together these two mutations generated
approximately a 10-fold weaker affinity for GdA in vitro
and 2.5-fold increases in IC(50) for GdA and 17-allylamino-
demethoxygeldanamycin inhibition of yeast growth in vivo
[21]. Importantly, E88G and N92L were unique amongst
the changes to the ADP/ATP site of S. hygroscopicus HtpG
in that they alone generated in the yeast Hsp90 a greater
relative increase in Kd for GdA, when compared with Kd
for ADP in vitro, as would be required for greater ATP
versus GdA occupancy of this nucleotide-binding site
in vivo. A crystal structure revealed that they weaken the
interactions of the chaperone with the C-12 methoxy
group on GdA (figure 1) [21].
Most fungi have just a single, essential, cytosolic form of
Hsp90 [59]. We investigated this Hsp90 from one of the
fungi producing RAD (the mycoparasite H. fuscoatra) to seewhether it is altered in its binding of ligands. The H. fuscoatra
Hsp90 was found to have a normal affinity for nucleotides
and GdA, but approximately eightfold weaker than
normal binding affinity for RAD [60]. However, unlike the
S. hygroscopicus HtpG, H. fuscoatra Hsp90 is largely unaltered
in the conserved amino acid residues of the Hsp90 ADP/
ATP-binding pocket. Its only novel feature is an isoleucine
replacement of normally conserved leucine at the base of this
pocket (figure 3). When introduced into the Hsp90 of yeast,
this single, conservative leucine to isoleucine change repro-
duced the weakened binding of RAD displayed by the
H. fuscoatra Hsp90 in vitro and, when expressed in the sole
Hsp90 of yeast cells, generated partial resistance to RAD
in vivo [60]. A crystal structure indicated that this leucine to iso-
leucine substitution acts to weaken RAD binding by causing an
increase in hydration in the vicinity of the bound RAD mol-
ecule [60]. Remarkably, Hsp90 of the RAD- and monocillin-
producing fungal pathogen of maize, Colletotrichum gramini-
cola, is altered in yet another highly conserved residue, a
methionine at the entrance to the ADP/ATP-binding pocket
(figure 3). While the effects of this methionine to phenylalanine
change have yet to be investigated, it is possible that it too
weakens the binding of these polyketides.7. Conclusions
The secondary metabolites of soil-dwelling actinomycetes
and fungi have long been the source of new antibiotics and
drug leads. The discovery of antibiotics highly selective for
Hsp90, and the subsequent development of drugs based
upon the molecular interactions made by these antibiotics
within the ADP/ATP-binding site of Hsp90 are a classic
example of this. Much attention now focuses on the clinical
trials of these drugs, especially as these are the only cancer
chemotherapeutic agents known to impact all six hallmarks
of cancer simultaneously [1,2]. While promising activity has
now been demonstrated in certain malignancies, certain of
the other trials have proved disappointing [1,2]. Designing
effective therapies around Hsp90 inhibitors will entail a
proper understanding of the molecular mechanisms whereby
cells are often refractory to their effects. Many aspects have to
be considered: such as differences in drug action on the var-
ious isoforms or conformations of Hsp90, dissimilarities in
drug metabolism, the effects of Hsp90 inhibition on both
normal and tumour cell physiology, the ability to cause
either cell stasis or apoptosis, or an inability to achieve an
effective level of drug in the tumour [36]. Most importantly,
these inhibitors cause a strong activation of the heat shock
response, leading to increases in the cellular levels of stress
proteins, proteins with largely pro-survival/anti-apoptotic
functions [36]. Drugs based on other, more recently identified
natural inhibitors of Hsp90 (table 1) may be able to overcome
some of these problems. Thus the induction of the anti-
apoptotic heat shock response seen with drugs that bind to
the ADP/ATP site of the Hsp90 N-terminal domain may be
avoided by switching to a new class of Hsp90 inhibitor
based on the interactions of novobiocin, the latter an agent
that interacts with the C-terminal region of the chaperone
(table 1; [61]).
However, inhibitors binding within the N-terminal
ADP/ATP site of Hsp90 have the potential attraction that
resistance might not emerge readily by mutation within
Figure 3. RAD, shown in yellow, bound within the N-terminal domain of the yeast Hsp90 (PDB ID: 1BGQ). Hsp90 residues forming the binding site of this antibiotic
molecule are shown in blue. Indicated in brown is the conserved leucine residue that is altered to an isoleucine in the Hsp90 of Humicola fuscoatra, thus generating
partial RAD resistance [60]. Indicated in magenta is the conserved methionine (Met84) that is altered to phenylalanine in Hsp90 of the maize pathogen
Colletotrichum graminicola.
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7this site. To date, it would appear that study of the Hsp90
family proteins of organisms that make Hsp90-targeting
antibiotics partly validates this prediction. Thus only partial,
not complete, resistance to either GdA or RAD has been
generated by introducing into the Hsp90 of yeast cells the
unusual features of the ADP/ATP-binding site of the
S. hygroscopicus HtpG or the H. fuscoatra Hsp90. Further-
more, the S. hygroscopicus HtpG—though resistant to
GdA—still has normal affinities for RAD and for other
inhibitors (NVP-AUY922 and VER49009) whose binding is
based on the interactions of RAD [21]. Conversely, the leu-
cine to isoleucine change in the H. fuscoatra Hsp90—while it
generates partial resistance to RAD—does not affect the
binding of GdA [60]. This suggests that, should mutations
such as these within the ADP/ATP-binding site of human
Hsp90 ever cause a degree of drug resistance in the clinic,
it should be possible to overcome this resistance by switch-
ing from an Hsp90 inhibitor based on the interactions of
GdA to one based on the interactions of RAD, or vice
versa. This is not to say that mutations located elsewhere
in Hsp90 cannot lead to resistance. Indeed an increased
Hsp90 inhibitor resistance is apparent with mutations that
increase the ATPase activity of the chaperone, at least in
cell culture systems [62,63].
Microbes making Hsp90 inhibitors may be resistant to their
antibiotic production for reasons other than a weakened bind-
ing of the antibiotic to the chaperone itself. While the
S. hygroscopicus HtpG exhibits no detectable binding of GdA[21], one cannot state with confidence that this confers
S. hygroscopicus with resistance to its production of this
antibiotic. Not only is HtpG protein absent, therefore nones-
sential, in a number of prokaryotes [59], but there is still no
evidence for any specific function for HtpG in a streptomycete.
Furthermore, antibiotic resistance in S. hygroscopicus is some-
times due to enzymes that modify the antibiotic molecule
[64]. Similarly, while the Hsp90 of the RAD-producing
fungus H. fuscoatra has a low binding affinity for RAD [60],
other factors may be of rather greater importance in rendering
such a fungus resistant to this antibiotic. Plasma membrane
drug efflux pumps elevate the cellular resistances of yeast to
GdA and RAD, acting to lower the intracellular levels of
these inhibitors [62]. Potentially such efflux activities could
be elevated in a RAD-producing fungus. Furthermore, as
with the streptomycetes, production of antibiotics by fungi
such as H. fuscoatra may be a starvation response, occurring
at locations distal from the actively growing hyphal tips and
serving mainly to defend the hyphal biomass against over-
growth by other organisms. Alternatively RAD resistance
might arise through reductions in the normal strong require-
ment for Hsp90 in fungal growth [39,40]. In those species
where it has been investigated, the signalling circuitry of
fungi is heavily dependent on Hsp90 [65]. Fungi that make
Hsp90 inhibitors may be adapted to partially overcome this,
such that a study of these species may be highly instructive
in terms of understanding the global influences of the
Hsp90 chaperone.
8Referencesrsob.royalsocietypublishing.org
Open
Biol2:1201381. Trepel J, Mollapour M, Giaccone G, Neckers L. 2010
Targeting the dynamic HSP90 complex in cancer. Nat.
Rev. Cancer 10, 537–549. (doi:10.1038/nrc2887)
2. Neckers L, Workman P. 2012 Hsp90 molecular
chaperone inhibitors: are we there yet? Clin. Cancer
Res. 18, 64–76. (doi:10.1158/1078-0432.CCR-11-
1000)
3. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm
MF, Fritz LC, Burrows FJ. 2003 A high-affinity
conformation of Hsp90 confers tumour selectivity on
Hsp90 inhibitors. Nature 425, 407–410. (doi:10.
1038/nature01913)
4. Balch WE, Morimoto RI, Dillin A, Kelly JW. 2008
Adapting proteostasis for disease intervention.
Science 319, 916–919. (doi:10.1126/science.
1141448)
5. Kikis EA, Gidalevitz T, Morimoto RI. 2010 Protein
homeostasis in models of aging and age-related
conformational disease. Adv. Exp. Med. Biol.
694, 138–159. (doi:10.1007/978-1-4419-7002-2_11)
6. Calamini B et al. 2012 Small-molecule proteostasis
regulators for protein conformational diseases. Nat.
Chem. Biol. 8, 185–196. (doi:10.1038/nchembio.763)
7. Geller R, Vignuzzi M, Andino R, Frydman J. 2007
Evolutionary constraints on chaperone-mediated
folding provide an antiviral approach refractory to
development of drug resistance. Genes Dev. 21,
195–205. (doi:10.1101/gad.1505307)
8. Shahinas D, Liang M, Datti A, Pillai DR. 2010 A
repurposing strategy identifies novel synergistic
inhibitors of Plasmodium falciparum heat shock
protein 90. J. Med. Chem. 53, 3552–3557. (doi:10.
1021/jm901796s)
9. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH. 1970
Geldanamycin, a new antibiotic. J. Antibiot. (Tokyo)
23, 442–447. (doi:10.7164/antibiotics.23.442)
10. Omura S, Iwai Y, Takahashi Y, Sadakane N,
Nakagawa A, Oiwa H, Hasegawa Y, Ikai T. 1979
Herbimycin, a new antibiotic produced by a strain of
Streptomyces. J. Antibiot. (Tokyo) 32, 255–261.
(doi:10.7164/antibiotics.32.255)
11. Tanida S, Hasegawa T, Higashide E. 1980 Macbecins
I and II, new antitumor antibiotics. I. Producing
organism, fermentation and antimicrobial activities.
J. Antibiot. (Tokyo) 33, 199–204. (doi:10.7164/
antibiotics.33.199)
12. Moulin E, Zoete V, Barluenga S, Karplus M,
Winssinger N. 2005 Design, synthesis, and biological
evaluation of HSP90 inhibitors based on
conformational analysis of radicicol and its
analogues. J. Am. Chem. Soc. 127, 6999–7004.
(doi:10.1021/ja043101w)
13. Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers
LM. 2000 The heat shock protein 90 antagonist
novobiocin interacts with a previously unrecognized
ATP-binding domain in the carboxyl terminus of the
chaperone. J. Biol. Chem. 275, 37 181–37 186.
(doi:10.1074/jbc.M003701200)
14. Shahinas D, Macmullin G, Benedict C, Crandall I,
Pillai DR. 2012 Harmine is a potent antimalarialtargeting Hsp90 and synergizes with chloroquine
and artemisinin. Antimicrob. Agents Chemother. 56,
4207–4213. (doi:10.1128/AAC.00328-12)
15. Palermo CM, Westlake CA, Gasiewicz TA. 2005
Epigallocatechin gallate inhibits aryl hydrocarbon
receptor gene transcription through an indirect
mechanism involving binding to a 90 kDa heat
shock protein. Biochemistry 44, 5041–5052.
(doi:10.1021/bi047433p)
16. Hastings JM, Hadden MK, Blagg BS. 2008 Synthesis
and evaluation of derrubone and select analogues.
J. Org. Chem. 73, 369–373. (doi:10.1021/
jo702366g)
17. Hieronymus H et al. 2006 Gene expression
signature-based chemical genomic prediction
identifies a novel class of HSP90 pathway
modulators. Cancer Cell 10, 321–330. (doi:10.1016/
j.ccr.2006.09.005)
18. Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D. 2009
Characterization of celastrol to inhibit hsp90 and
cdc37 interaction. J. Biol. Chem. 284,
35 381–35 389. (doi:10.1074/jbc.M109.051532)
19. Yu Y et al. 2010 Withaferin A targets heat shock
protein 90 in pancreatic cancer cells. Biochem.
Pharmacol. 79, 542–551. (doi:10.1016/j.bcp.2009.
09.017)
20. Davenport J, Manjarrez JR, Peterson L, Krumm B,
Blagg BS, Matts RL. 2011 Gambogic acid, a natural
product inhibitor of Hsp90. J. Nat. Prod. 74,
1085–1092. (doi:10.1021/np200029q)
21. Millson SH, Chun C-S, Roe SM, Polier S, Solovieva S,
Pearl LH, Sim T-S, Prodromou C, Piper PW. 2011
Features of the Streptomyces hygroscopicus HtpG
reveal how partial geldanamycin resistance can arise
by mutation to the ATP binding pocket of a
eukaryotic Hsp90. FASEB J. 25, 3828–3837.
(doi:10.1096/fj.11-188821)
22. Sasaki K, Yasuda H, Onodera K. 1979 Growth
inhibition of virus transformed cells in vitro and
antitumor activity in vivo of geldanamycin and its
derivatives. J. Antibiot. (Tokyo) 32, 849–851.
(doi:10.7164/antibiotics.32.849)
23. Whitesell L, Mimnaugh EG, De Costa B, Myers CE,
Neckers LM. 1994 Inhibition of heat shock protein
HSP90-pp60v-src heteroprotein complex formation
by benzoquinone ansamycins: essential role for
stress proteins in oncogenic transformation. Proc.
Natl Acad. Sci. USA 91, 8324–8328. (doi:10.1073/
pnas.91.18.8324)
24. Schneider C, Sepp-Lorenzino L, Nimmesgern E,
Ouerfelli O, Danishefsky S, Rosen N, Hartl FU. 1996
Pharmacologic shifting of a balance between
protein refolding and degradation mediated by
Hsp90. Proc. Natl Acad. Sci. USA 93, 14 536–
14 541. (doi:10.1073/pnas.93.25.14536)
25. Whitesell L, Cook P. 1996 Stable and specific
binding of heat shock protein 90 by geldanamycin
disrupts glucocorticoid receptor function in intact
cells. Mol. Endocrinol. 10, 705–712. (doi:10.1210/
me.10.6.705)26. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl
FU, Pavletich NP. 1997 Crystal structure of an
Hsp90–geldanamycin complex: targeting of a
protein chaperone by an antitumor agent. Cell 89,
239–250. (doi:10.1016/S0092-8674(00)80203-2)
27. Prodromou C, Roe SM, O’Brien R, Ladbury JE, Piper
PW, Pearl LH. 1997 Identification and structural
characterization of the ATP/ADP-binding site in the
Hsp90 molecular chaperone. Cell 90, 65–75.
(doi:10.1016/S0092-8674(00)80314-1)
28. Zhou H, Qiao K, Gao Z, Vederas JC, Tang Y. 2010
Insights into radicicol biosynthesis via heterologous
synthesis of intermediates and analogs. J. Biol.
Chem. 285, 41 412–41 421. (doi:10.1074/jbc.M110.
183574)
29. Kwon HJ, Yoshida M, Fukui Y, Horinouchi S, Beppu
T. 1992 Potent and specific inhibition of p60v-src
protein kinase both in vivo and in vitro by radicicol.
Cancer Res. 52, 6926–6930.
30. Roe SM, Prodromou C, O’Brien R, Ladbury JE, Piper
PW, Pearl LH. 1999 Structural basis for inhibition of
the Hsp90 molecular chaperone by the antitumor
antibiotics radicicol and geldanamycin. J. Med.
Chem. 42, 260–266. (doi:10.1021/jm980403y)
31. Porter JR, Ge J, Lee J, Normant E, West K. 2009
Ansamycin inhibitors of Hsp90: nature’s prototype
for anti-chaperone therapy. Curr. Top. Med. Chem. 9,
1386–1418. (doi:10.2174/156802609789895719)
32. Amolins MW, Blagg BS. 2009 Natural product
inhibitors of Hsp90: potential leads for drug
discovery. Mini Rev. Med. Chem. 9, 140–152.
(doi:10.2174/138955709787316056)
33. Kang MJ, Strap JL, Crawford DL. 2010 Isolation and
characterization of potent antifungal strains of the
Streptomyces violaceusniger clade active against
Candida albicans. J. Ind. Microbiol. Biotechnol. 37,
35–41. (doi:10.1007/s10295-009-0641-9)
34. Rascher A, Hu Z, Buchanan GO, Reid R, Hutchinson
CR. 2005 Insights into the biosynthesis of the
benzoquinone ansamycins geldanamycin and
herbimycin, obtained by gene sequencing and
disruption. Appl. Environ. Microbiol. 71, 4862–4871.
(doi:10.1128/AEM.71.8.4862-4871.2005)
35. Qin HL, Panek JS. 2008 Total synthesis of the Hsp90
inhibitor geldanamycin. Org. Lett. 10, 2477–2479.
(doi:10.1021/ol800749w)
36. Piper PW, Millson SH. 2011 Mechanisms of
resistance to Hsp90 inhibitor drugs: a complex
mosaic emerges. Pharmaceuticals 4, 1400–1422.
(doi:10.3390/ph4111400)
37. Wu CZ et al. 2011 New non-quinone geldanamycin
analogs from genetically engineered Streptomyces
hygroscopicus. J. Antibiot. (Tokyo) 64, 461–463.
(doi:10.1038/ja.2011.24)
38. Chater KF, Biro S, Lee KJ, Palmer T, Schrempf H.
2010 The complex extracellular biology of
Streptomyces. FEMS Microbiol. Rev. 34, 171–198.
(doi:10.1111/j.1574-6976.2009.00206.x)
39. Millson SH, Truman A, King V, Prodromou C, Pearl L,
Piper PW. 2005 A two-hybrid screen of the yeast
rsob.royalsocietypublishing.org
Open
Biol2:120138
9proteome for Hsp90 interactors uncovers a novel
Hsp90 chaperone requirement in activity of a stress-
activated MAP kinase, Slt2p(Mpk1p). Eukaryot. Cell
4, 849–860. (doi:10.1128/EC.4.5.849-860.2005)
40. LaFayette SL, Collins C, Zaas AK, Schell WA,
Betancourt-Quiroz M, Gunatilaka AA, Perfect JR,
Cowen LE. 2010 PKC signaling regulates drug
resistance of the fungal pathogen Candida albicans
via circuitry comprised of Mkc1, calcineurin, and
Hsp90. PLoS Pathog. 6, e1001069. (doi:10.1371/
journal.ppat.1001069)
41. Reeves CD, Hu Z, Reid R, Kealey JT. 2008 Genes for
the biosynthesis of the fungal polyketides
hypothemycin from Hypomyces subiculosus and
radicicol from Pochonia chlamydosporia. Appl.
Environ. Microbiol. 74, 5121–5129. (doi:10.1128/
AEM.00478-08)
42. Wang S, Xu Y, Maine EA, Wijeratne EM, Espinosa-
Artiles P, Gunatilaka AA, Molnar I. 2008 Functional
characterization of the biosynthesis of radicicol, an
Hsp90 inhibitor resorcylic acid lactone from
Chaetomium chiversii. Chem. Biol. 15, 1328–1338.
(doi:10.1016/j.chembiol.2008.10.006)
43. Delmotte P, Delmotte-Plaque J. 1953 A new
antifungal substance of fungal origin. Nature 171,
344–346. (doi:10.1038/171344a0)
44. Ayer WA, Lee SP, Tsuneda A, Hiratsuka Y. 1980 The
isolation, identification, and bioassay of the
antifungal metabolites produced by Monocillium
nordinii. Can. J. Microbiol. 26, 766–773. (doi:10.
1139/m80-133)
45. Evans G, White NH. 1966 Radicicolin and radicicol,
two new antibiotics produced by Cylindrocarpon
radicicola. Trans. Br. Mycol. Soc. 49, 563–576.
(doi:10.1016/S0007-1536(66)80004-9)
46. Wijeratne EM et al. 2004 Isolation, optimization of
production and structure–activity relationship studies
of monocillin I, the cytotoxic constituent of
Paraphaeosphaeria quadriseptata. J. Antibiot. (Tokyo)
57, 541–546. (doi:10.7164/antibiotics.57.541)
47. McLellan CA, Turbyville TJ, Wijeratne EM, Kerschen
A, Vierling E, Queitsch C, Whitesell L, Gunatilaka AA.
2007 A rhizosphere fungus enhances Arabidopsis
thermotolerance through production of an HSP90
inhibitor. Plant Physiol. 145, 174–182. (doi:10.
1104/pp.107.101808)48. Turbyville TJ et al. 2006 Search for Hsp90 inhibitors
with potential anticancer activity: isolation and SAR
studies of radicicol and monocillin I from two plant-
associated fungi of the Sonoran desert. J. Nat. Prod.
69, 178–184. (doi:10.1021/np058095b)
49. Morton OM, Hirsch PR, Kerry BR. 2004 Infection of
plant-parasitic nematodes by nematophagous fungi:
a review of the application of molecular biology to
understand infection processes and to improve
biological control. Nematology 6, 161–170. (doi:10.
1163/1568541041218004)
50. Wicklow DT, Joshi BK, Gamble WR, Gloer JB, Dowd
PF. 1998 Antifungal metabolites (monorden,
monocillin IV, and cerebrosides) from Humicola
fuscoatra traaen NRRL 22980, a mycoparasite of
Aspergillus flavus sclerotia. Appl. Environ. Microbiol.
64, 4482–4484.
51. Wicklow DT, Jordan AM, Gloer JB. 2009 Antifungal
metabolites (monorden, monocillins I, II, III) from
Colletotrichum graminicola, a systemic vascular
pathogen of maize. Mycol. Res. 113, 1433–1442.
(doi:10.1016/j.mycres.2009.10.001)
52. Sutherland ED, Baker KK, Lockwood JL. 1984
Ultrastructure of Phytophthora megasperma f. sp.
glycinea oospores parasitised by Actinoplanes
missouriensis and Humicola fuscoatra. Trans. Br.
Mycol. Soc. 82, 726–729. (doi:10.1016/S0007-
1536(84)80117-5)
53. de la Fuente van Bentem S et al. 2005 Heat shock
protein 90 and its co-chaperone protein
phosphatase 5 interact with distinct regions of the
tomato I-2 disease resistance protein. Plant J. 43,
284–298. (doi:10.1111/j.1365-313X.2005.02450.x)
54. Kadota Y, Shirasu K. 2012 The HSP90 complex of
plants. Biochim. Biophys. Acta 1823, 689–697.
(doi:10.1016/j.bbamcr.2011.09.016)
55. Belkhadir Y, Subramaniam R, Dangl JL. 2004 Plant
disease resistance protein signaling: NBS-LRR
proteins and their partners. Curr. Opin. Plant Biol. 7,
391–399. (doi:10.1016/j.pbi.2004.05.009)
56. Anderson RG et al. 2012 Homologous RXLR effectors
from Hyaloperonospora arabidopsidis and Phytophthora
sojae suppress immunity in distantly related plants.
Plant J. (doi:10.1111/j.1365-313X.2012.05079.x)
57. Gorre ME, Mohammed M, Ellwood K, Hsu N,
Paquette R, Rao PN, Sawyers CL. 2001 Clinicalresistance to STI-571 cancer therapy caused by BCR-
ABL gene mutation or amplification. Science 293,
876–880. (doi:10.1126/science.1062538)
58. Yun CH, Mengwasser KE, Toms AV, Woo MS,
Greulich H, Wong KK, Meyerson M, Eck MJ. 2008
The T790M mutation in EGFR kinase causes drug
resistance by increasing the affinity for ATP. Proc.
Natl Acad. Sci. USA 105, 2070–2075. (doi:10.1073/
pnas.0709662105)
59. Chen B, Zhong D, Monteiro A. 2006 Comparative
genomics and evolution of the HSP90 family of genes
across all kingdoms of organisms. BMC Genomics 7,
156. (doi:10.1186/1471-2164-7-156)
60. Prodromou C, Nuttall JM, Millson SH, Roe SM, Sim
TS, Tan D, Workman P, Pearl LH, Piper PW. 2009
Structural basis of the radicicol resistance displayed
by a fungal hsp90. ACS Chem. Biol. 4, 289–297.
(doi:10.1021/cb9000316)
61. Shelton SN et al. 2009 KU135, a novel
novobiocin-derived C-terminal inhibitor of the 90-
kDa heat shock protein, exerts potent
antiproliferative effects in human leukemic cells.
Mol. Pharmacol. 76, 1314–1322. (doi:10.1124/
mol.109.058545)
62. Millson SH, Prodromou C, Piper PW. 2010 A simple
yeast-based system for analyzing inhibitor resistance
in the human cancer drug targets Hsp90alpha/beta.
Biochem. Pharmacol. 79, 1581–1588. (doi:10.1016/
j.bcp.2010.01.031)
63. Zurawska A, Urbanski J, Matuliene J, Baraniak J,
Klejman MP, Filipek S, Matulis D, Bieganowski P.
2010 Mutations that increase both Hsp90 ATPase
activity in vitro and Hsp90 drug resistance in vivo.
Biochim. Biophys Acta 1803, 575–583. (doi:10.
1016/j.bbamcr.2010.03.002)
64. Pardo JM, Malpartida F, Rico M, Jimenez A. 1985
Biochemical basis of resistance to hygromycin B in
Streptomyces hygroscopicus: the producing
organism. J. Gen. Microbiol. 131, 1289–1298.
(doi:10.1099/00221287-131-6-1289)
65. Diezmann S, Michaut M, Shapiro RS, Bader GD,
Cowen LE. 2012 Mapping the Hsp90 genetic
interaction network in Candida albicans reveals
environmental contingency and rewired circuitry.
PLoS Genet. 8, e1002562. (doi:10.1371/journal.
pgen.1002562)
